Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CONX vs ABVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 8–0 Matrix Metrics)

ABVX Overall Winner 6-Pillar Tally: CONX 1 – 2 ABVX (3 Tie) Matrix Metrics: CONX 0 – 8 ABVX

As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVX carries 55.3/100 (HOLD) at $83.61 (N/M Forward P/E, -6270.4% operating margin).

  • Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CONX vs ABVX
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.88β · 135% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $4.23 · SMA50: $5.78
ABVX NASDAQ Head-to-Head Winner
Abivax SA American Depositary Shares
Pharmaceutical Preparations
$83.61
-4.53% 1D
Market Cap $7.7B
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.40β · 49% Vol
Unified Composite Score
55.3 / 100 HOLD
Tech 42.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.1%), weak momentum, RSI 41
RSI-14: 40.5 · SMA20: $88.33 · SMA50: $94.23

6-Pillar Scorecard Institutional Category Breakdown (CONX 1 – 2 ABVX)

Columns: Metric · CONX · ABVX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABVX
Revenue Growth (YoY) N/A -6.8%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $4.7M
Market Cap N/A $7.7B
3. Profitability & Quality ABVX
Gross Margin N/A 100.0%
Operating Margin N/A -6270.4%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -252.3%
4. Balance Sheet & Cash Flow CONX
Cash Generation (TTM) N/A -$292M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $5.16 Book/Sh · -252.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 76.9% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CONX (0) vs ABVX (8)
Institutional Metric CONX ABVX Criterion Row Edge
Market Capitalization
Scale
N/A $7.7B Larger Scale ABVX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -6.8% Higher Growth ABVX
Operating Margin (TTM)
Profitability
N/A -6270.4% Higher Margin ABVX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABVX
Return on Equity (ROE)
Capital Efficiency
N/A -252.3% Higher ROE ABVX
52-Week Range Position
Momentum
0% ($3–$28) 18% ($70–$149) Stronger Trend ABVX
Beta / 30D Volatility
Risk Regime
4.88β · 135% Vol 1.40β · 49% Vol Lower Realized Risk ABVX
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 55.3 / 100 (HOLD) Higher Composite ABVX
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$292M EBITDA ($5.16 Book/Sh · -252.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVX +49.53 pp
CONX: -54.66% · ABVX: -5.13%
3M Horizon ABVX +14.64 pp
CONX: -44.34% · ABVX: -29.7%
6M Horizon ABVX +44.89 pp
CONX: -71.26% · ABVX: -26.37%
1Y Horizon ABVX +62.99 pp
CONX: -88.97% · ABVX: -25.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs ABVX. Trailing 12-month operating profitability (CONX N/A vs ABVX -6270.4%) and valuation multiples (CONX N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABVX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin100.0%
Op. Margin-6270.4%
ROE / Fwd P/E-252.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.7B market capitalization and -6270.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CONX vs ABVX Key Questions & Quantitative Answers

As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CONX carries a Unified Composite Score of 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin), whereas ABVX carries 55.3/100 (HOLD) at $83.61 (N/M Forward P/E, -6270.4% operating margin). Technical & Structure Timing Caution: CONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVX leads the Growth & Scale pillar: CONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, CONX generates N/A in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, CONX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.

CONX and ABVX trade at balanced relative valuation multiples. CONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CONX (N/A ROE) versus ABVX (-252.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CONX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 135% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.